Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha …

Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha …

“While there have been recent advances in the treatment of prostate cancer, there remains a great need for therapies that can more specifically target primary and metastatic prostate cancer,” said Mark R. Baker, Chief Executive Officer of Progenics.

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Write a comment

*